KR20220002965A - 리포산 프로드러그 - Google Patents

리포산 프로드러그 Download PDF

Info

Publication number
KR20220002965A
KR20220002965A KR1020217037290A KR20217037290A KR20220002965A KR 20220002965 A KR20220002965 A KR 20220002965A KR 1020217037290 A KR1020217037290 A KR 1020217037290A KR 20217037290 A KR20217037290 A KR 20217037290A KR 20220002965 A KR20220002965 A KR 20220002965A
Authority
KR
South Korea
Prior art keywords
different
same
compound
substituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217037290A
Other languages
English (en)
Korean (ko)
Inventor
마사토모 가토
도모코 오다
신지 다카오카
다카히로 혼다
다츠야 하타
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20220002965A publication Critical patent/KR20220002965A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217037290A 2019-04-17 2020-04-16 리포산 프로드러그 Ceased KR20220002965A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019078798 2019-04-17
JPJP-P-2019-078798 2019-04-17
PCT/JP2020/016774 WO2020213693A1 (ja) 2019-04-17 2020-04-16 リポ酸プロドラッグ

Publications (1)

Publication Number Publication Date
KR20220002965A true KR20220002965A (ko) 2022-01-07

Family

ID=72837203

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037290A Ceased KR20220002965A (ko) 2019-04-17 2020-04-16 리포산 프로드러그

Country Status (9)

Country Link
US (1) US20220151989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3957365A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2020213693A1 (cg-RX-API-DMAC7.html)
KR (1) KR20220002965A (cg-RX-API-DMAC7.html)
CN (1) CN113710320A (cg-RX-API-DMAC7.html)
AU (1) AU2020258729A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136938A1 (cg-RX-API-DMAC7.html)
TW (1) TW202103696A (cg-RX-API-DMAC7.html)
WO (1) WO2020213693A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147957A2 (en) 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11269170A (ja) * 1997-04-02 1999-10-05 Sankyo Co Ltd ジチオラン誘導体
CZ96798A3 (cs) * 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2010147962A1 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
CA2941518A1 (en) * 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147957A2 (en) 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[비특허문헌 1] 아따라시이 안과, Vol.28, No.7, 985-988, 2011
본 명세서에 있어서 인용하는 선행기술문헌의 개시는 전부 참조함으로써 본 명세서에 삽입된다.

Also Published As

Publication number Publication date
US20220151989A1 (en) 2022-05-19
EP3957365A4 (en) 2023-01-11
TW202103696A (zh) 2021-02-01
CA3136938A1 (en) 2020-10-22
EP3957365A1 (en) 2022-02-23
JPWO2020213693A1 (cg-RX-API-DMAC7.html) 2020-10-22
AU2020258729A1 (en) 2021-11-11
WO2020213693A1 (ja) 2020-10-22
CN113710320A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
ES2733092T3 (es) Derivados de benzodioxol como inhibidores de la fosfodiesterasa
KR102902220B1 (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
JP2011510965A (ja) 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体
US20250034193A1 (en) Phenothiazine derivatives and uses thereof
EA015971B1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
KR20210105916A (ko) 우루소데옥시콜산을 함유하는 노시의 치료 또는 예방제
KR20220002965A (ko) 리포산 프로드러그
JP2010514733A (ja) 高眼圧症の治療のためのイソソルビドモノニトレート誘導体
CA3214066A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
WO2020243720A1 (en) Pharmacological agents for treating protein aggregation diseases of the eye
EP3697412B1 (en) A compound for treating osteoarthritis
US20250115596A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
ES2717481T3 (es) Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos
US20220371988A1 (en) Trpv1 agonist and preparation method therefor and use thereof
WO2023058673A1 (ja) 老視等の治療または予防に有用な含硫黄化合物
KR20230015955A (ko) 노시의 치료 또는 예방에 유용한 황 함유 화합물
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601